Researchers have identified a specific cellular mechanism that contributes to reduced neurogenesis in Down syndrome. A new study published in EMBO Reports provides evidence that elevated mitochondrial metabolism in induced pluripotent stem cells (iPSCs) derived from individuals with Down syndrome (DS) reduces their ability to commit to neuroectoderm (NE). This commitment represents one of the earliest steps in the development of the nervous system. The findings suggest that a mitochondria-to-cilia signaling axis is dysregulated in DS iPSCs, offering a potential target for therapeutic intervention.
Down syndrome is the most common genetic cause of intellectual disability, occurring at a frequency of approximately 1 out of every 700 live births. A key feature of the condition is an overall reduction in brain size and neuronal density, particularly in regions involved in executive function and memory. While it has been known for over sixty years that inheriting an extra copy of human chromosome 21 causes DS, the specific molecular mechanisms responsible for cognitive differences have remained elusive. The study aims to determine whether the capacity for neurogenesis is impacted at the earliest stages of lineage commitment.
The study utilized isogenic pairs of iPSCs derived from individuals with Down syndrome, designated as 3S-iPSCs, and their euploid controls, designated as 2S-iPSCs. The primary lines were derived from skin fibroblasts of a 1-year-old male with DS, while a secondary pair was derived from renal epithelial cells of a 46-year-old female with DS. These isogenic pairs allow for a direct comparison of cellular properties while controlling for genetic background. The researchers assessed the ability of these cells to commit to NE under both directed and spontaneous differentiation protocols.
Under directed differentiation conditions, cultures derived from 3S-iPSCs showed a significantly lower frequency of cells positive for PAX6, a key marker of the NE lineage, compared to 2S-iPSC controls. Transcript levels of PAX6 increased over 100-fold in the euploid cultures, whereas the increase in the trisomic cultures was significantly less. Similar results were observed during spontaneous differentiation, where the frequency of cells staining positive for PAX6 and another NE marker, OTX2, was reduced in the DS-derived cultures. These findings suggest that a cell-autonomous factor contributes to reduced neurogenesis in DS at the earliest stages of lineage commitment.
The study found that DS 3S-iPSCs proliferate more rapidly than their euploid counterparts. Flow cytometric analysis revealed that a greater percentage of 3S-iPSCs were in the S phase of the cell cycle, while a lower percentage were in the G1/G0 phase. This shorter cell cycle reduces the opportunity for the growth of a primary cilium, a non-motile, antenna-like structure that acts as a signaling hub for developmental pathways. The primary cilium is formed during the G1 phase and must be disassembled upon entry into S phase to allow for centrosome replication.
Immunofluorescence microscopy showed that after 48 hours of spontaneous differentiation, approximately 30% of cells in the 2S-derived cultures were positive for both pericentrin (PCNT) and ARL13B, indicating the presence of a primary cilium. In contrast, cilia-positive cells were rare in the 3S-derived cultures. To verify the importance of the primary cilium in NE commitment, the researchers used siRNA to knock down genes essential for cilia formation, such as KIF3A and IFT20, in the euploid 2S-iPSCs. This knockdown significantly reduced the percentage of cells with primary cilia and also reduced PAX6 transcript levels and fluorescence intensity, confirming the role of the cilium in directing stem cells toward the neurogenic lineage.
The study further demonstrated that the increased proliferation in DS iPSCs is driven by elevated mitochondrial activity. Mitochondria in 3S-iPSCs exhibited higher membrane potential and increased capacity for calcium uptake via the mitochondrial calcium uniporter (MCU) compared to controls. Calcium uptake is dependent on mitochondrial membrane potential and promotes progression through the cell cycle by activating enzymes in the TCA cycle to increase ATP production. Inhibiting MCU activity with specific inhibitors, such as Ru265, or using siRNA to deplete MCU, increased the fraction of cells in G1/G0 and restored ciliation in the DS iPSCs.
Pharmacological interventions were tested to determine if the reduced commitment to NE could be reversed. The researchers tested fluoxetine, metformin, and nobiletin, three compounds that have been reported to increase neurogenesis and promote cell cycle arrest at G1/G0. Pretreating 3S-iPSCs with these compounds significantly decreased the fraction of cells in S phase and increased ciliation on day 2 of differentiation. All three drugs also increased PAX6 transcript levels and median fluorescence intensity on day 5 of differentiation, suggesting that slowing proliferation and increasing time spent in G1 is sufficient to improve commitment to NE in DS iPSCs.
The findings were consistent across both male and female isogenic iPSC lines, indicating that the reduced capacity for early commitment toward the NE lineage is independent of sex and genetic background. The study also noted that commitment to other lineages, such as endoderm and mesoderm, was reduced in DS iPSCs, though the impact was most pronounced on NE. This suggests a generalized delay in stem cell commitment that could contribute to other DS-associated developmental delays, such as congenital heart defects.
The authors propose a model in which elevated mitochondrial metabolic activity and MCU capacity in DS iPSCs increase the rate of proliferation, thereby reducing time spent in G1 and the growth of primary cilia required for commitment to NE. While the study provides strong evidence for this mechanism in vitro, the authors caution that further studies are needed to understand the role of this signaling axis in vivo. The findings highlight mitochondrial metabolism and MCU capacity as potential nodal points for therapeutic targeting, regardless of the specific genetic cause of the metabolic phenotype.
Additionally, the drug treatments were restricted to a short window of time and were removed when cultures were released to differentiate. The authors emphasize that neurogenesis is a multi-step developmental process with dynamic changes in mitochondrial activity, and it is possible that the mitochondria-to-cilia signaling axis could have different effects at later stages. Further investigation is required to determine if interventions to reduce mitochondrial activity would be beneficial at specific stages of development.
The study was conducted using human induced pluripotent stem cells rather than animal models, a design choice the authors highlight as a significant strength. Mouse models of Down syndrome, while valuable, may not fully capture the earliest deficiencies in human neuronal development. For instance, the maturation of the mitochondrial network in newly formed neurons is species-specific; human neurons take several months to mature in culture, whereas mouse neurons complete this process in a matter of weeks. Additionally, a human-specific modifier gene, CROCCP2, has been identified that promotes the expansion of cortical progenitors by decreasing ciliogenesis. This suggests that the mitochondria-to-cilia signaling axis described in the study may have a more substantial impact on neurogenesis in humans than in mice, as it could influence the critical expansion of cortical progenitor cells.
The research also examined whether the observed cellular defects were specific to the neuroectoderm lineage or indicative of a broader developmental delay. Using directed differentiation protocols, the investigators tested the ability of the trisomic iPSCs to commit to endoderm and mesoderm, both of which contribute to the specification and differentiation of the myocardium. Commitment to these lineages was also reduced compared to the isogenic euploid controls. Tracking the expression of lineage markers during the first three days of spontaneous differentiation indicated that while the impact on neuroectoderm commitment was the most pronounced, there was a trend suggesting reduced commitment to the other two lineages as well. This generalized delay in stem cell commitment raises the possibility that it could contribute to other Down syndrome-associated developmental delays, such as congenital heart defects, which occur in approximately half of babies born with the condition.
Genetic factors on chromosome 21 may also play a role in the observed ciliation defects. Several cilia-related genes are located on human chromosome 21, including Pericentrin (PCNT), which has a dose-dependent impact on the primary cilium. The increased dosage of PCNT in trisomic cells likely affects aspects of ciliation. However, genetic analysis of patients with partial trisomy 21 suggests that triplication of PCNT is not strictly required to manifest the intellectual disabilities and craniofacial features of Down syndrome. The experiments in this study indicate that elevated mitochondrial metabolic activity lies upstream of the reduced ciliation, suggesting that the metabolic phenotype is a primary driver. Whether a specific gene, a combination of genes, or the state of aneuploidy itself is responsible for the increased mitochondrial activity remains to be determined, but the findings highlight mitochondrial metabolism as a potential nodal point for therapeutic targeting regardless of the specific genetic cause.
The authors emphasize that the pharmacological interventions tested, such as fluoxetine, metformin, and nobiletin, were applied during a short, controlled window and removed before differentiation began. This approach allowed for a focused assessment of the pluripotent state but does not provide insight into what an appropriate in vivo level of stem cell commitment might be or whether such interventions would be beneficial in a living organism. Metformin, for example, has been shown to increase neurogenesis in some animal models, but daily administration to pregnant rats has been reported to negatively impact the neocortical development of the offspring. Therefore, extreme caution is warranted, and further studies are essential to understand the role of this signaling axis in vivo before it can be considered a viable therapeutic target for Down syndrome.
Subject of Research: Mitochondrial metabolism and primary cilia in Down syndrome iPSC neuroectoderm commitment
Article Title: Elevated mitochondrial metabolism in Down syndrome iPSCs reduces commitment to neuroectoderm
Article References: Chaklader, M., Souza Bomfim, G. H., Zhu, J., Jeju, N., Nguyen, T., Duan, Y., Niemeyer, B. F., Espinosa, J. M., Rosado-Olivieri, E., Lin, W., Lacruz, R. S., & Rothermel, B. A. (2026). Elevated mitochondrial metabolism in Down syndrome iPSCs reduces commitment to neuroectoderm. EMBO Reports. https://doi.org/10.1038/s44319-026-00944-9
Image Credits: AI Generated
DOI: 10.1038/s44319-026-00944-9
Keywords: Down syndrome, iPSCs, mitochondrial metabolism, neuroectoderm, primary cilia, MCU, cell cycle, neurogenesis, stem cells, EMBO Reports, Elevated, mitochondrial
News Source: Daisy Hatcher. (November 13, 2026). Down Syndrome Stem Cells Show Mitochondrial Metabolism Delays Neuroectoderm Commitment. Scienmag.
